DK1802581T3 - 4-[(2,4-Dichlor-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolincarbonitriller til behandling af iskæmisk beskadigelse - Google Patents

4-[(2,4-Dichlor-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolincarbonitriller til behandling af iskæmisk beskadigelse

Info

Publication number
DK1802581T3
DK1802581T3 DK05820982T DK05820982T DK1802581T3 DK 1802581 T3 DK1802581 T3 DK 1802581T3 DK 05820982 T DK05820982 T DK 05820982T DK 05820982 T DK05820982 T DK 05820982T DK 1802581 T3 DK1802581 T3 DK 1802581T3
Authority
DK
Denmark
Prior art keywords
ethynyl
methoxyphenyl
dichloro
alkoxy
amino
Prior art date
Application number
DK05820982T
Other languages
Danish (da)
English (en)
Inventor
Diane Harris Boschelli
Margaret Zaleska
Ana Carolina Barrios-Sosa
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1802581T3 publication Critical patent/DK1802581T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05820982T 2004-10-22 2005-10-21 4-[(2,4-Dichlor-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolincarbonitriller til behandling af iskæmisk beskadigelse DK1802581T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22
PCT/US2005/037839 WO2006047262A1 (en) 2004-10-22 2005-10-21 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury

Publications (1)

Publication Number Publication Date
DK1802581T3 true DK1802581T3 (da) 2008-06-30

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05820982T DK1802581T3 (da) 2004-10-22 2005-10-21 4-[(2,4-Dichlor-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolincarbonitriller til behandling af iskæmisk beskadigelse

Country Status (23)

Country Link
US (1) US20060116375A1 (cg-RX-API-DMAC10.html)
EP (1) EP1802581B1 (cg-RX-API-DMAC10.html)
JP (1) JP2008517924A (cg-RX-API-DMAC10.html)
KR (1) KR20070085413A (cg-RX-API-DMAC10.html)
CN (1) CN101044117A (cg-RX-API-DMAC10.html)
AT (1) ATE391122T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005299822A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0516995A (cg-RX-API-DMAC10.html)
CA (1) CA2581807A1 (cg-RX-API-DMAC10.html)
CR (1) CR9072A (cg-RX-API-DMAC10.html)
DE (1) DE602005005843T2 (cg-RX-API-DMAC10.html)
DK (1) DK1802581T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP077385A (cg-RX-API-DMAC10.html)
ES (1) ES2303287T3 (cg-RX-API-DMAC10.html)
IL (1) IL182547A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007004833A (cg-RX-API-DMAC10.html)
NO (1) NO20071708L (cg-RX-API-DMAC10.html)
PL (1) PL1802581T3 (cg-RX-API-DMAC10.html)
PT (1) PT1802581E (cg-RX-API-DMAC10.html)
RU (1) RU2007111704A (cg-RX-API-DMAC10.html)
SI (1) SI1802581T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006047262A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200703275B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
WO2014086284A1 (zh) * 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Also Published As

Publication number Publication date
KR20070085413A (ko) 2007-08-27
AU2005299822A1 (en) 2006-05-04
CR9072A (es) 2007-09-07
MX2007004833A (es) 2007-05-16
PT1802581E (pt) 2008-06-03
EP1802581B1 (en) 2008-04-02
WO2006047262A1 (en) 2006-05-04
NO20071708L (no) 2007-07-13
ATE391122T1 (de) 2008-04-15
DE602005005843T2 (de) 2009-05-14
CN101044117A (zh) 2007-09-26
CA2581807A1 (en) 2006-05-04
EP1802581A1 (en) 2007-07-04
DE602005005843D1 (de) 2008-05-15
ECSP077385A (es) 2007-05-30
PL1802581T3 (pl) 2008-09-30
ES2303287T3 (es) 2008-08-01
JP2008517924A (ja) 2008-05-29
US20060116375A1 (en) 2006-06-01
IL182547A0 (en) 2007-09-20
SI1802581T1 (sl) 2008-08-31
HK1104555A1 (en) 2008-01-18
BRPI0516995A (pt) 2008-09-30
RU2007111704A (ru) 2008-11-27
ZA200703275B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
JO2282B1 (en) Oxazole derivatives
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
JP2018509418A5 (cg-RX-API-DMAC10.html)
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
ATE501141T1 (de) Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
EA200700756A1 (ru) Пиримидоны
EA201270266A1 (ru) Гетероциклические соединения
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
WO2008155669A3 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MY145066A (en) Methods for treating sexual dysfunction
RU2007116987A (ru) Новые соединения
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
EA200701780A1 (ru) Противоопухолевое средство
IL182547A0 (en) 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
PT100332A (pt) Agentes para o tratamento de doencas cardiovasculares derivados de piridina e imidazole
DK1634595T3 (da) N-Phenylbenzamidderivater som medikamenter til behandling af kronisk obstruktiv lungesygdom (KOL)
EA201071259A1 (ru) Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов